BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 19007372)

  • 21. Lymphovascular invasion is an independent predictor of prostate-specific antigen failure after radical prostatectomy in patients with pT3aN0 prostate cancer.
    Yamamoto S; Kawakami S; Yonese J; Fujii Y; Ohkubo Y; Suyama T; Komai Y; Kijima T; Ishikawa Y; Fukui I
    Int J Urol; 2008 Oct; 15(10):895-9. PubMed ID: 18721204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of body mass index and total testosterone level on biochemical recurrence following radical prostatectomy.
    Hisasue S; Yanase M; Shindo T; Iwaki H; Fukuta F; Nishida S; Muranaka T; Miyamoto S; Tsukamoto T; Takatsuka K
    Jpn J Clin Oncol; 2008 Feb; 38(2):129-33. PubMed ID: 18281308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE.
    Bassett WW; Cooperberg MR; Sadetsky N; Silva S; DuChane J; Pasta DJ; Chan JM; Anast JW; Carroll PR; Kane CJ
    Urology; 2005 Nov; 66(5):1060-5. PubMed ID: 16286124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic.
    Price MM; Hamilton RJ; Robertson CN; Butts MC; Freedland SJ
    Urology; 2008 May; 71(5):787-91. PubMed ID: 18267334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Obesity is not associated with aggressive pathologic features or biochemical recurrence after radical prostatectomy.
    Tomaszewski JJ; Chen YF; Bertolet M; Ristau BT; Woldemichael E; Nelson JB
    Urology; 2013 May; 81(5):992-6. PubMed ID: 23453649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Obesity and capsular incision at the time of open retropubic radical prostatectomy.
    Freedland SJ; Grubb KA; Yiu SK; Nielsen ME; Mangold LA; Isaacs WB; Epstein JI; Partin AW
    J Urol; 2005 Nov; 174(5):1798-801; discussion 1801. PubMed ID: 16217290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database.
    Freedland SJ; Hotaling JM; Fitzsimons NJ; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL
    Eur Urol; 2008 Apr; 53(4):758-64; discussion 765-6. PubMed ID: 17868976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era.
    Gjertson CK; Asher KP; Sclar JD; Goluboff ET; Olsson CA; Benson MC; McKiernan JM
    Urology; 2007 Oct; 70(4):723-7. PubMed ID: 17991544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
    Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
    Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The risk of upstaged disease increases with body mass index in low-risk prostate cancer patients eligible for active surveillance.
    Ploussard G; de la Taille A; Bayoud Y; Durand X; Terry S; Xylinas E; Allory Y; Vacherot F; Abbou CC; Salomon L
    Eur Urol; 2012 Feb; 61(2):356-62. PubMed ID: 21803484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation of High Body Mass Index With More Advanced Localized Prostate Cancer at Radical Prostatectomy Is Not Reflected in PSA Level and PSA Density but Is Seen in PSA Mass.
    Kryvenko ON; Epstein JI; Meier FA; Gupta NS; Menon M; Diaz M
    Am J Clin Pathol; 2015 Aug; 144(2):271-7. PubMed ID: 26185312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer.
    Efstathiou JA; Chen MH; Renshaw AA; Loffredo MJ; D'Amico AV
    Cancer; 2007 Apr; 109(8):1493-8. PubMed ID: 17340594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
    Culp S; Porter M
    BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of body mass index on histopathologic parameters: results of large European contemporary consecutive open radical prostatectomy series.
    Isbarn H; Jeldres C; Budäus L; Salomon G; Schlomm T; Steuber T; Chun FK; Ahyai S; Capitanio U; Haese A; Heinzer H; Huland H; Graefen M; Karakiewicz P
    Urology; 2009 Mar; 73(3):615-9. PubMed ID: 19010520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy.
    Yamamoto S; Yonese J; Kawakami S; Ohkubo Y; Tatokoro M; Komai Y; Takeshita H; Ishikawa Y; Fukui I
    Eur Urol; 2007 Sep; 52(3):696-701. PubMed ID: 17412490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer.
    Boormans JL; Wildhagen MF; Bangma CH; Verhagen PC; van Leenders GJ
    BJU Int; 2008 Dec; 102(11):1589-93. PubMed ID: 18710447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system.
    van Oort IM; Witjes JA; Kok DE; Kiemeney LA; Hulsbergen-Van De Kaa CA
    BJU Int; 2008 Aug; 102(4):438-41. PubMed ID: 18336608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
    Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
    Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of obesity on tumour volume in patients with prostate cancer.
    Capitanio U; Suardi N; Briganti A; Gallina A; Abdollah F; Lughezzani G; Salonia A; Freschi M; Montorsi F
    BJU Int; 2012 Mar; 109(5):678-84. PubMed ID: 21777363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
    Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
    Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.